Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN107,9108,2-1,92
Msft-0,13
Nokia5,8665,921,16
IBM1,10
Mercedes-Benz Group AG57,5857,60,89
PFE0,40
14.02.2026 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 13.02.2026
ClearPoint Neuro Rg (NASDAQ Cons)
Závěr k 13.2.2026 Změna (%) Změna (USD) Objem obchodů (USD)
13,55 3,91 0,51 6 656 668
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 14.02.2026
Popis společnosti
Obecné informace
Název společnostiClearpoint Neuro Inc
TickerCLPT
Kmenové akcie:Ordinary Shares
RICCLPT.O
ISIN-
Prioritní akciePreference Shares
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky30.09.2025
Počet zaměstnanců k 18.02.2025 115
Akcie v oběhu k 20.11.2025 29 748 308
MěnaUSD
Kontaktní informace
Ulice120 S. SIERRA AVENUE, SUITE 100
MěstoSOLANA BEACH
PSČ92075
ZeměUnited States
Kontatní osobaDanilo D' Alessandro
Funkce kontaktní osobyChief Financial Officer
Telefon19 499 006 833
Fax19499006834

Business Summary: ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. It provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. It provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. It also offers IRRAflow active fluid-exchange system.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Clearpoint Neuro Inc revenues increased 12% to $26.6M. Net loss increased 31% to $17.8M. Revenues reflect Products: Functional neurosurgery segment increase of 37% to $10.1M, Products: Biologics and drug delivery segment increase of 15% to $4.9M. Higher net loss reflects General and administrative expenses increase of 33% to $7.6M (expense).
Odvětvová klasifikace
TRBC2009Advanced Medical Equipment
TRBC2012Advanced Medical Equipment & Technology (NEC)
RBSS2004Biotechnology
MGINDUSTRYMedical Equipment & Supplies
MGSECTORHealthcare
NAICSElectromedical and Electrotherapeutic Apparatus Manufacturing
NAICSSurgical and Medical Instrument Manufacturing
NAICSSoftware Publishers
NAICS2007Electromedical Apparatus Mfg
NAICS2007Surgical & Medical Instrument Mfg
NAICS1997Electromedical and Electrotherapeutic Apparatus Manufacturing
NAICS1997Surgical and Medical Instrument Manufacturing
SICSurgical And Medical Instruments
SICElectromedical Equipment
SICSurgical And Medical Instruments
SICPrepackaged Software



  • Poslední aktualizace: 14.02.2026
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorJoseph Burnett4807.11.201707.11.2017
Chief Financial OfficerDanilo D' Alessandro4029.09.2020
Chief Operating OfficerMazin Sabra4510.10.202210.10.2022
Chief Business OfficerJeremy Stigall42